Related references
Note: Only part of the references are listed.Trends in clinical development for PD-1/PD-L1 inhibitors
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Combining microenvironment normalization strategies to improve cancer immunotherapy
Fotios Mpekris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
Da-Hyun Kim et al.
BMB REPORTS (2020)
Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy
Jing Han et al.
JOURNAL OF CANCER (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.
Jeeyun Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jozsef Jaszai et al.
CELLS (2019)
Aptamers in the Therapeutics and Diagnostics Pipelines
Harleen Kaur et al.
THERANOSTICS (2018)
Anti-Angiogenics: Current Situation and Future Perspectives
Katja Zirlik et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Valentina Comunanza et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
Dongheon Lee et al.
MABS (2016)
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
Frank Kuhnert et al.
CANCER RESEARCH (2015)
Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
Kiersten Marie Miles et al.
PLOS ONE (2014)
Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer
Muxing Kang et al.
CANCER LETTERS (2013)
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Matthew Ohr et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Takuya Kuramoto et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Anti-VEGF Therapies in the Clinic
Kellen L. Meadows et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
Ji-Liang Li et al.
CANCER RESEARCH (2011)
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You et al.
CANCER RESEARCH (2011)
Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Qingbei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hiroya Hashizume et al.
CANCER RESEARCH (2010)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
Timothy Hoey et al.
CELL STEM CELL (2009)
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Ji-Liang Li et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Anti-DII4 therapy: can we block tumour growth by increasing angiogenesis?
Richard C. A. Sainson et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Irene Noguera-Troise et al.
NATURE (2006)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Pegaptanib for the treatment of age-related macular degeneration
Bo Zhou et al.
EXPERIMENTAL EYE RESEARCH (2006)
Recombinant approaches to IgG-like bispecific antibodies
JS Marvin et al.
ACTA PHARMACOLOGICA SINICA (2005)
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development
NW Gale et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II
H Wildiers et al.
BRITISH JOURNAL OF CANCER (2003)
Share Paper
